Daunorubicin, Cytarabine, and Cladribine Regimen Plus Radiotherapy and Donor Lymphocyte Infusion for Extramedullary Relapse of Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation | Zendy

Marco Sanna | Zendy; Giovanni Caocci | Zendy; Adriana Vacca | Zendy; Eugenia Piras | Zendy; Federica Orrù | Zendy; Giorgio La Nasa | Zendy

Open Access

Daunorubicin, Cytarabine, and Cladribine Regimen Plus Radiotherapy and Donor Lymphocyte Infusion for Extramedullary Relapse of Acute Myeloid Leukemia after Hematopoietic Stem Cell Transplantation

Author(s) -

Marco Sanna,

Giovanni Caocci,

Adriana Vacca,

Eugenia Piras,

Federica Orrù,

Giorgio La Nasa

Publication year - 2013

Publication title -

case reports in hematology

Language(s) - English

Resource type - Journals

eISSN - 2090-6560

pISSN - 2090-6579

DOI - 10.1155/2013/258028

Subject(s) - medicine , cytarabine , cladribine , myeloid leukemia , hematopoietic stem cell transplantation , regimen , daunorubicin , radiation therapy , transplantation , myeloid , oncology , myeloid sarcoma , stem cell , leukemia , surgery , biology , genetics

Myeloid sarcoma is a rare tumor consisting of myeloid blasts that involve anatomic sites outside the bone marrow. Fatal prognosis is inevitable in patients with extramedullary relapse after hematopoietic stem cell transplantation (HSCT), and no standard treatments are available yet. We report the first case of extramedullary relapse after HSCT treated with a combination of daunorubicin, cytarabine, and cladribine (DAC) regimen plus radiotherapy and donor lymphocyte infusion (DLI). This treatment induced a new and durable remission in our patient. The favorable toxicity profile and the reduced cost make this combination worthy of further investigations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research